Abstract:BACKGROUND: Comparative evaluation of surgical quality among hospitals must improve outcome and efficiency, and reduce medical costs. Reoperation after colorectal surgery is a consequence of surgical complications and therefore considered a quality-of-care indicator. With respect to the mortality rate, the 1-year mortality may be a more meaningful figure than in-hospital mortality, because it also reflects the impact of surgical complications beyond discharge. OBJECTIVE: The aim of our study was to evaluate the 1-year mortality after colorectal surgery and to identify predicting factors. DESIGN: This study was a retrospective analysis from our colorectal surgery database. PATIENTS: All patients who underwent elective colorectal surgery from 2005 to 2008 were included. MAIN OUTCOME MEASURES: Both univariate and multivariate analysis were performed to identify predicting factors. The following variables were analyzed: age, operative risk according to the ASA class, Charlson-Age Comorbidity Index, indication for and type of resection, primary anastomosis, tumor staging, anastomotic leakage, and reoperation. RESULTS: For 743 consecutive patients, the 1-year mortality rate was 6.9%. Patients were operated on mainly because of colorectal cancer (n = 537; 72%). The rate of reoperation and in-hospital mortality was 12.8% and 2.4%. Univariate survival analysis demonstrated that ASA class, age, Charlson-Age Comorbidity Index, reoperation, and stage of disease were independent predictors of 1-year mortality. Multivariate analysis showed that ASA class (P = .020; HR 1.69), age (P = .015; HR 2.08) and reoperation (P = .001; HR 2.72) are directly correlated with 1-year mortality. LIMITATIONS: Both patients with benign diseases and colorectal cancer are included. Furthermore, no clear guidelines on whether to perform a reoperation were available. CONCLUSION: One-year mortality after colorectal surgery is independently predicted by ASA class, age, and reoperation. Our results underline the value of the 1-year mortality rate and the reoperation rate as parameters for quality assessment in colorectal surgery.

Smart Erythrocyte-Hitchhiking Insulin Delivery System for Prolonged Automatic Blood Glucose Control

Ultrafast Glucose-Responsive, High Loading Capacity Erythrocyte to Self-Regulate the Release of Insulin

Glucose-responsive erythrocyte-bound nanoparticles for continuously modulated insulin release

Red Blood Cells for Glucose-Responsive Insulin Delivery

Oral delivery of insulin with intelligent glucose-responsive switch for blood glucose regulation

Injectable Nano-Network for Glucose-Mediated Insulin Delivery.

Erythrocyte-Membrane-Enveloped Biomineralized Metal-Organic Framework Nanoparticles Enable Intravenous Glucose-Responsive Insulin Delivery

An Intelligent Nanoscale Insulin Delivery System

Erythrocyte-mimicking subcutaneous platform with a laser-controlled treatment against diabetes

On-demand transdermal insulin delivery system for type 1 diabetes therapy with no hypoglycemia risks

Hypoxia and H2o2 Dual-Sensitive Vesicles for Enhanced Glucose-Responsive Insulin Delivery

Ultrasound-triggered noninvasive regulation of blood glucose levels using microgels integrated with insulin nanocapsules

Microneedles with Two-Stage Glucose-Sensitive Controlled Release for Long-Term Insulin Delivery.

Renal denervation as a friend of catheter ablation in patients with atrial fibrillation and hypertension

Intelligent Microneedle Patch Based on Functionalized Alginate and Chitosan for Long-Term Self-Regulated Insulin Delivery

Glucose-responsive nanoparticles designed via a molecular-docking-driven method for insulin delivery

Functional Nanochaperones for PEGylated Insulin Delivery in Long-Term Glycemic Control

Reoperation After Colorectal Surgery Is an Independent Predictor of the 1-Year Mortality Rate

On demand regulation of blood glucose level by biocompatible oxidized starch-Con A nanogels for glucose-responsive release of exenatide

Glucose and H2O2 dual-sensitive nanogels for enhanced glucose-responsive insulin delivery

Engineering Synthetic Insulin-Secreting Cells Using Hyaluronic Acid Microgels Integrated with Glucose-Responsive Nanoparticles